Generic Pristiq launched by Mylan
CANONSBURG – Mylan N.V. Friday announced the U.S. launch of Desvenlafaxine Extended-release Tablets in 50- and 100-mg doses.
The drug, which is indicated for the treatment of major depressive disorder, is a generic version of Pfizer’s Pristiq tablets.
Mylan, whose adminstrative headquarteres are in Southpointe, received final approval from the U.S. Food and Drug Administration.
The tablets had U.S. sales of approximately $853 million for the 12 months ending Jan. 31, according to IMS Health.